10-K: Regeneron Pharmaceuticals CEO and CFO Certify Accuracy of 2023 Annual Report

Regeneron Pharmaceuticals' CEO and CFO have certified the accuracy and completeness of the company's 2023 annual report on Form 10-K, ensuring compliance with SEC regulations.

Summary

• Regeneron Pharmaceuticals' CEO and CFO have certified the company's 2023 annual report on Form 10-K, confirming its accuracy and compliance with SEC rules.
• The certification covers the financial statements, other financial information, and the effectiveness of disclosure controls and procedures.
• The officers also confirmed the design and maintenance of internal controls over financial reporting.
• The certification includes disclosure of any changes in internal controls that could materially affect financial reporting.
• The officers have disclosed any significant deficiencies or material weaknesses in internal controls to the company's auditors and audit committee.
• The certification also covers any fraud involving management or employees with a significant role in internal controls.

Sentiment

Score: 7

Explanation: The document is a standard compliance report, so the sentiment is neutral to slightly positive due to the assurance it provides. It is not a business update, so it is not highly positive.

Positives

• The CEO and CFO's certification provides assurance of the accuracy and reliability of the company's financial reporting.
• The certification confirms the effectiveness of the company's internal controls and disclosure procedures.
• The disclosure of any changes in internal controls ensures transparency and accountability.

Risks

• The document highlights the responsibility of the CEO and CFO for the accuracy of financial reporting, implying potential liability if misstatements are found.
• The document mentions the disclosure of significant deficiencies or material weaknesses in internal controls, which could indicate potential risks in the company's financial reporting processes.
• The document also mentions the disclosure of any fraud involving management or employees with a significant role in internal controls, which could indicate potential risks in the company's ethical conduct.

Management Comments

• The CEO and CFO have certified that the report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, not misleading.
• The CEO and CFO have certified that the financial statements fairly present the financial condition, results of operations, and cash flows of the company.

Industry Context

This type of certification is a standard requirement for public companies under the Sarbanes-Oxley Act, ensuring accountability and transparency in financial reporting.

Comparison to Industry Standards

• The certification process is a standard practice for all publicly traded companies in the US, as mandated by the Sarbanes-Oxley Act of 2002.
• The specific language and requirements of the certification are consistent with SEC guidelines and industry best practices.
• The level of detail and scope of the certification are comparable to those of other large pharmaceutical and biotechnology companies.

Stakeholder Impact

• The certification provides assurance to shareholders about the accuracy of the company's financial reporting.
• The certification ensures compliance with regulatory requirements, which is important for investor confidence.
• The certification also provides assurance to other stakeholders, such as creditors and employees, about the company's financial health.

Key Dates

Keywords

certification, financial reporting, internal controls, disclosure controls, SEC, Form 10-K, CEO, CFO, Sarbanes-Oxley Act, financial statements